Human eIF5A2 adenoviral particles

Eukaryotic translation initiation factor 5A2 (eIF5A2) is a member of the eIF5A family and plays a critical role in protein synthesis, cell proliferation, and survival. Unlike its paralog eIF5A1, eIF5A2 is often overexpressed in various cancers, including hepatocellular carcinoma, colorectal cancer, and ovarian cancer, which leads to tumor progression, metastasis, and poor prognosis. The activity of this protein depends on hypoalanylation, a post-translational modification that is essential for its function. eIF5A2 regulates the translation of specific mRNAs involved in cell cycle regulation, apoptosis, and stress response, making it a potential therapeutic target. Its oncogenic properties and its association with aggressive cancer phenotypes have stimulated intense interest in studying its molecular mechanisms and exploring strategies to regulate its expression or activity.

Human eIF5A2 adenoviral particles are genetically engineered viral vectors designed to efficiently deliver the eIF5A2 gene to target cells. Adenoviruses are a preferred choice for gene delivery due to their ability to infect both dividing and non-dividing cells, high transduction efficiency, and ability to carry large gene inserts. These particles are replication-defective, which prevents uncontrolled viral replication in host cells, thus ensuring safety. Human eIF5A2 adenoviral particles are used by researchers to overexpress eIF5A2 in vitro or in vivo to study its biological functions, such as its role in cancer progression, metastasis, and drug resistance. In addition, these particles can be used for functional rescue experiments or to study downstream signaling pathways.